Retatrutide Prescribing Information: Why No FDA Label Exists
Retatrutide has no FDA prescribing information. That is not an oversight or a document that is hard to find. Prescribing information is created through approval, and retatrutide has not been approved.
Medically reviewed by Valeria Marulanda, FNP-BCIf you have been shown a document described as retatrutide prescribing information, it did not come from the FDA. No such label exists for this compound.
What prescribing information actually is
Prescribing information, also called the package insert or the label, is a regulated document the FDA approves at the same time it approves a drug. It is not written by a marketer or compiled from studies. It is agreed between the sponsor and the agency, and its structure is set by regulation.
A modern US label opens with a Highlights section and then runs through numbered sections in a fixed order: indications and usage, dosage and administration, dosage forms and strengths, contraindications, warnings and precautions, adverse reactions, drug interactions, and use in specific populations.
Every one of those sections depends on a completed review. An indication states which patients the drug is approved to treat. A dosage section states an approved dose. Neither can exist before a regulator has granted approval for a defined use.
Why retatrutide has none
Retatrutide is investigational. It has completed Phase 2 studies and, as of 2026, has Phase 3 programs in progress with some topline results reported by the sponsor. None of that is approval, and approval is the event that produces a label.
Sponsor-reported topline results are announcements, not regulatory findings. They typically precede peer-reviewed publication and always precede an agency decision. A drug can report strong topline numbers and still not be approved, be approved for a narrower population than the one studied, or be approved with warnings that appeared in no press release.
What exists instead
Four kinds of document exist in place of a label. Every one of them describes what was studied rather than what a regulator has authorised, which is why none of them can substitute for prescribing information. A trial protocol is a research plan for supervised participants, not a set of instructions for anyone else.
- Peer-reviewed publications of completed trials, reporting methods, dose arms and outcomes for the studied population only
- ClinicalTrials.gov registry records, giving protocol design, status, eligibility criteria and locations
- Sponsor topline announcements, reporting headline outcomes ahead of publication
- The investigator brochure, which is provided to trial sites and is not a public document
What an approved drug in this class looks like
Tirzepatide and semaglutide are useful reference points because they reached approval. Both have full FDA prescribing information published through the agency’s own channels, with approved indications, dosing schedules, contraindications and boxed warnings where applicable.
That is the concrete difference between an approved medicine and an investigational compound. One has a document a clinician can prescribe from. The other has research literature. Retatrutide is currently in the second category.
How to verify any document you are shown
- Genuine US labels are published by the FDA through Drugs@FDA and DailyMed. If a document is not there, it is not an FDA label.
- A real label names an approved indication and an approved dose. A document describing a compound as being for research use only is not a label.
- Sellers of research material sometimes present protocol tables or study summaries in a label-like layout. Format is not authority.
- Approval status can change. Check the registry and the agency directly rather than relying on any third-party page, including this one.
When prescribing information would appear
A label becomes possible only after a sponsor submits a marketing application, the agency completes its review and an approval is granted for a specific indication. Publication in the FDA’s own databases follows that decision.
Until then, no document describes an approved retatrutide dose, because no approved dose exists.
Common Questions
Where can I find retatrutide prescribing information?
Nowhere, because it does not exist. Prescribing information is produced through FDA approval, and retatrutide is not approved.
Is retatrutide FDA approved in 2026?
No. Phase 3 studies have progressed and the sponsor has reported topline results, but reported results are not a regulatory decision and retatrutide remains investigational.
Does a Phase 3 topline result mean approval is close?
Not necessarily. Topline results precede peer-reviewed publication and any agency review. Approval, its timing, its indication and its labeled warnings are all decided afterward.
Someone sent me a retatrutide package insert. Is it real?
It is not an FDA label. Genuine US labels are published through Drugs@FDA and DailyMed. A document formatted to look like a label carries no regulatory status.
Is there an approved retatrutide dose?
No. Published trials describe the dose arms used under supervision in research. Those are study designs, not an approved dosing schedule.
References
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. 2023;389:514–526.
- ClinicalTrials.gov. TRIUMPH-1: A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight. NCT05929066. Record updated June 2026.
- Eli Lilly and Company. TRIUMPH-1 Phase 3 topline results and American Diabetes Association 86th Scientific Sessions program update. May 2026.
References were checked against the journal, PubMed or ClinicalTrials.gov record. Company-reported topline results are labeled as such.